A Phase 2 Study To Evaluate The Safety Of Apixaban In Atrial Fibrillation

A Phase 2b, Randomized, Partially Blind (Open Label Warfarin), Active-Controlled (Warfarin), Multicenter Study, To Evaluate The Safety And Efficacy In 2 Doses Of Apixaban In Comparison To Warfarin, Administered For 12 Weeks In Subjects With NVAF

To assess the effect of two doses of Apixaban (2.5 mg BID and 5 mg BID) versus Warfarin on the composite endpoint of major and clinically relevant non-major bleeding during the treatment period.

Inclusion Criteria:

• Age ≥ 20 years outpatient (regardless of sex)
• Patients diagnosed as non-valvular atrial fibrillation (NVAF)
• One or more following risks of stroke.

Exclusion Criteria:

• Recent cerebral infarction (includes TIA) within 4 weeks of week 0.
• Subjects who have or are suspected to have a serious/hereditary bleeding tendency, such as disseminated intravascular coagulation syndrome (DIC), congenital platelet dysfunction and von Willebrand disease (those suspected from the family history are included).
• Subjects who have or are suspected to have a serious/hereditary thrombogenic tendency (those suspected from the family history are included) or those who require continuation of the Warfarin therapy.